Office of Innovation and Industry Alliances

Media and NewsAvailable TechnologiesInternship Programs

Office of Innovation and Industry Alliances

Moffitt’s Office of Technology Management and Commercialization (OTMC) changed its name to the Office of Innovation and Industry Alliances, or Innovation Office. Since 2004, the Innovation Office is credited with a total of 66 United States patents issued and 160 license agreements executed, as well as approximately $30 million in industry alliances funding for Moffitt in the past year and a half.

The Innovation Office serves as Moffitt’s tech transfer entity that identifies new and exciting research discoveries that have potential commercial value and works to bring them to market. In addition, a greater emphasis is placed on forging research industry alliances, which align with Moffitt’s Research Strategic Plan - Research Financial Viability & Expanding Moffitt’s Innovation Portfolio. Some of the prominent new industry alliances include Celgene, Forma Therapeutics, and Lion Biotechnologies, which provide Moffitt with critical research funding and access to novel technologies and technical expertise.

Why Moffitt?

  • 3rd largest US cancer center by patient volume, with over 330,000 outpatient visits annually and over 200 active clinical studies.
  • NCI Comprehensive Cancer Center, one of only 45 nationwide and the only one based in Florida. This distinction recognizes Moffitt’s excellence in research, contributions to clinical trials, and cancer prevention and control. 
  • Over 300 research and clinical faculty members create an innovation hotbed where clinically useful discoveries are being moved from the laboratory bench to the patient’s bedside.

Building Alliances

Biomedical Industry – Moffitt has licensing and research collaboration opportunities. Click here for available technologies.
Professional Executives and Investors – Moffitt faculty startups are seeking mentors, professional management, and investors. Click here to learn about Moffitt faculty startups.